With Roche Opting Out, ArQule Uncertain On Plans For E2F Oncology Program
This article was originally published in The Pink Sheet Daily
Well-capitalized biotech had planned to launch Phase I investigation of E2F molecule in 2009 before Roche’s unexpected decision.
You may also be interested in...
Two deals bring the biotech $75 million upfront, plus research and clinical development funding.
Genentech’s announcement that Roche’s $89 per share bid undervalues the biotech comes as little surprise. But how much is Roche willing to pay?
As the ongoing COVID-19 pandemic forces health care to go digital, opportunities for fraud have proliferated. In Vivo explores the risks, the steps regulators are taking and how companies are looking to provide innovative solutions to help secure manufacturing supply chains.